Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewImmunologyOncology Open Access | 10.1172/jci.insight.208950

Effects of calreticulin mutations on HLA class I expression in myeloproliferative neoplasms

Amanpreet Kaur,1 Grace Pagnucco,1 Fawziyah S. Khatri,1 Harini Desikan,1 Malathi Kandarpa,2 Matthew Cusick,3 Moshe Talpaz,2 and Malini Raghavan1

1Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, United States of America

2Department of Internal Medicine, Division of Hematology/Oncology, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, United States of America

3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America

Find articles by Kaur, A. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, United States of America

2Department of Internal Medicine, Division of Hematology/Oncology, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, United States of America

3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America

Find articles by Pagnucco, G. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, United States of America

2Department of Internal Medicine, Division of Hematology/Oncology, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, United States of America

3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America

Find articles by Khatri, F. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, United States of America

2Department of Internal Medicine, Division of Hematology/Oncology, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, United States of America

3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America

Find articles by Desikan, H. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, United States of America

2Department of Internal Medicine, Division of Hematology/Oncology, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, United States of America

3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America

Find articles by Kandarpa, M. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, United States of America

2Department of Internal Medicine, Division of Hematology/Oncology, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, United States of America

3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America

Find articles by Cusick, M. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, United States of America

2Department of Internal Medicine, Division of Hematology/Oncology, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, United States of America

3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America

Find articles by Talpaz, M. in: PubMed | Google Scholar

1Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, United States of America

2Department of Internal Medicine, Division of Hematology/Oncology, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, United States of America

3Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America

Find articles by Raghavan, M. in: PubMed | Google Scholar

Published November 10, 2026 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.208950.
Copyright © 2026, Kaur et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published November 10, 2026 - Version history
View PDF
Abstract

Essential thrombocythemia (ET) and myelofibrosis (MF) are myeloproliferative neoplasms (MPN) that can result from heterozygous or homozygous mutations in the calreticulin (CRT) gene (CALR). Mutant CRT binds to the thrombopoietin receptor to induce signaling that drives ET and MF. CRT is also a chaperone for the assembly of the highly polymorphic human leukocyte antigen (HLA) class I molecules. The effects of heterozygous versus homozygous MPN CALR mutations on the expression of HLA class I variants are unknown. To assess mutant CRT-induced changes to HLA class I expression, we generated CRISPR-based mutant CALR knock-in cell lines and CALR-knockout cell lines reconstituted with wild-type or MPN mutant CALR and also undertook measurements in MPN patient platelets and monocytes. Collectively, our findings indicate that heterozygous CALR mutations preserve HLA class I surface expression, whereas full loss of wild-type CRT results in marked, allele-dependent reductions in HLA class I expression, which are rescued by wild-type CRT but not MPN mutants. Reduced expression of CRT-dependent HLA class I in cells lacking a functional CRT induces natural killer (NK) cell activation. These studies identify specific HLA class I alleles and homozygous CALR mutations as prerequisites for low HLA class I expression in MPN.

Graphical Abstract
graphical abstract
Supplemental material

View Unedited blot and gel images

View

Version history
  • Version 1 (November 10, 2026): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts